Essais liés10clinical trials
VilleShinjuku-Kulocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT04396574

Ouvrir le site du centre

Essais cliniques associés

10
MoléculeIndication / populationPhaseNCTTitreStatut
Lasmiditan Migraine Phase 3 NCT04396236 PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine TERMINATED
Erenumab Dose 1 Migraine Phase 3 NCT03832998 OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine COMPLETED
Galcanezumab Migraine Phase 3 NCT04616326 REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ACTIVE_NOT_RECRUITING
Lasmiditan Migraine Phase 3 NCT04396574 PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine TERMINATED
Telitacicept Myasthénie Phase 3 NCT06456580 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) RECRUITING
Galcanezumab Migraine Phase 3 NCT03432286 REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ACTIVE_NOT_RECRUITING
Erenumab Dose 1 Migraine Phase 3 NCT03836040 OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine ACTIVE_NOT_RECRUITING
Rimegepant Migraine Phase 3 NCT05156398 Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects RECRUITING
Rimegepant/BHV3000 Migraine Phase 3 NCT04649242 Randomized Study in Children and Adolescents With Migraine: Acute Treatment RECRUITING
Efgartigimod PH20 SC Myasthénie Phase 3 NCT06558279 ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis ACTIVE_NOT_RECRUITING